The functional and therapeutic difference in these two designations are exemplified by the actions of newer anti-diabetes drugs—these drugs including sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists have beneficial effects in large clinical trials where cardiovascular events and deaths are reduced by treatment with the index agents. The gene discussed is GCG; the disease is diabetes mellitus.